Patent for Copaxone ceased in 2014 , but pesumbaly the two companies are working together as NSB would need to source Copaxone part of the product or the news story attached (dated 2018) might also explain https://www.fiercepharma.com/pharma/facing-generics-from-mylan-and-novartis-teva-loses-patent-appeal-copaxone "Teva's patent failure gives long-acting Copaxone generics free rein"
Patent for Copaxone ceased in 2014 , but pesumbaly the two...
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.363M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.4¢ | 4.2¢ | $3.383K | 79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3284 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.5¢ |
Change
0.000 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 4.5¢ | 4.5¢ | 4.5¢ | 11200 | ||
| Last updated 12.20pm 22/05/2024 ? | |||||
| NSB (ASX) Chart |